AR041947A1 - Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas - Google Patents
Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericasInfo
- Publication number
- AR041947A1 AR041947A1 ARP030104151A ARP030104151A AR041947A1 AR 041947 A1 AR041947 A1 AR 041947A1 AR P030104151 A ARP030104151 A AR P030104151A AR P030104151 A ARP030104151 A AR P030104151A AR 041947 A1 AR041947 A1 AR 041947A1
- Authority
- AR
- Argentina
- Prior art keywords
- peripheral neuropathies
- carnitine
- acetyl
- administration
- pharmaceutically acceptable
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 6
- 208000027232 peripheral nervous system disease Diseases 0.000 title abstract 5
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 201000001119 neuropathy Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- -1 taxanes Chemical class 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960003433 thalidomide Drugs 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/292,823 US20030199535A1 (en) | 1998-07-30 | 2002-11-13 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041947A1 true AR041947A1 (es) | 2005-06-01 |
Family
ID=32312146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104151A AR041947A1 (es) | 2002-11-13 | 2003-11-12 | Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030199535A1 (enExample) |
| EP (1) | EP1562577B1 (enExample) |
| JP (1) | JP2006508958A (enExample) |
| KR (1) | KR20050075012A (enExample) |
| CN (1) | CN1708297A (enExample) |
| AR (1) | AR041947A1 (enExample) |
| AT (1) | ATE526958T1 (enExample) |
| AU (2) | AU2003283807B2 (enExample) |
| BR (1) | BR0316131A (enExample) |
| CA (1) | CA2505937C (enExample) |
| CY (1) | CY1112399T1 (enExample) |
| DK (1) | DK1562577T3 (enExample) |
| ES (1) | ES2374503T3 (enExample) |
| MX (1) | MXPA05004752A (enExample) |
| PL (1) | PL379244A1 (enExample) |
| PT (1) | PT1562577E (enExample) |
| SI (1) | SI1562577T1 (enExample) |
| TW (1) | TWI362260B (enExample) |
| WO (1) | WO2004043454A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018767A2 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ITMI20070817A1 (it) * | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi |
| JP4208036B1 (ja) * | 2007-04-26 | 2009-01-14 | 日本新薬株式会社 | 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 |
| WO2009028605A1 (ja) * | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | 抗がん剤による末梢神経障害の予防又は軽減剤 |
| AU2008348717B2 (en) * | 2007-10-30 | 2013-09-19 | Trophos | Novel composition for treating the side effects of anticancer treatments |
| EA201170732A1 (ru) * | 2008-12-01 | 2011-12-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| ITPZ20130005A1 (it) * | 2013-07-05 | 2015-01-06 | Teodosio Antonio Ferrara | Metabolismo energetico e omeostasi |
| CN110121563A (zh) | 2016-11-09 | 2019-08-13 | 奇根科学有限责任公司 | 在边合成边测序中作为成像试剂的光保护混合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713370A (en) * | 1972-11-06 | 1987-12-15 | Felice Stephen L De | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats |
| US4599352A (en) * | 1984-03-01 | 1986-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic platinum (IV) complexes and compositions |
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| DE69923322T2 (de) * | 1998-07-30 | 2005-12-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung |
-
2002
- 2002-11-13 US US10/292,823 patent/US20030199535A1/en not_active Abandoned
-
2003
- 2003-10-23 PT PT03775788T patent/PT1562577E/pt unknown
- 2003-10-23 KR KR1020057008678A patent/KR20050075012A/ko not_active Ceased
- 2003-10-23 ES ES03775788T patent/ES2374503T3/es not_active Expired - Lifetime
- 2003-10-23 WO PCT/IT2003/000656 patent/WO2004043454A1/en not_active Ceased
- 2003-10-23 AU AU2003283807A patent/AU2003283807B2/en not_active Ceased
- 2003-10-23 CA CA2505937A patent/CA2505937C/en not_active Expired - Fee Related
- 2003-10-23 BR BR0316131-5A patent/BR0316131A/pt not_active IP Right Cessation
- 2003-10-23 CN CNA2003801022169A patent/CN1708297A/zh active Pending
- 2003-10-23 JP JP2004551161A patent/JP2006508958A/ja active Pending
- 2003-10-23 PL PL379244A patent/PL379244A1/pl unknown
- 2003-10-23 SI SI200332090T patent/SI1562577T1/sl unknown
- 2003-10-23 EP EP03775788A patent/EP1562577B1/en not_active Expired - Lifetime
- 2003-10-23 DK DK03775788.7T patent/DK1562577T3/da active
- 2003-10-23 MX MXPA05004752A patent/MXPA05004752A/es active IP Right Grant
- 2003-10-23 AT AT03775788T patent/ATE526958T1/de active
- 2003-10-30 TW TW092130286A patent/TWI362260B/zh not_active IP Right Cessation
- 2003-11-12 AR ARP030104151A patent/AR041947A1/es not_active Application Discontinuation
-
2006
- 2006-04-13 US US11/402,961 patent/US20060183798A1/en not_active Abandoned
-
2009
- 2009-04-08 AU AU2009201384A patent/AU2009201384A1/en not_active Abandoned
-
2012
- 2012-01-03 CY CY20121100001T patent/CY1112399T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003283807A1 (en) | 2004-06-03 |
| PT1562577E (pt) | 2012-01-12 |
| EP1562577B1 (en) | 2011-10-05 |
| ES2374503T3 (es) | 2012-02-17 |
| CY1112399T1 (el) | 2015-12-09 |
| BR0316131A (pt) | 2005-09-27 |
| US20060183798A1 (en) | 2006-08-17 |
| US20030199535A1 (en) | 2003-10-23 |
| TW200410683A (en) | 2004-07-01 |
| JP2006508958A (ja) | 2006-03-16 |
| SI1562577T1 (sl) | 2012-01-31 |
| PL379244A1 (pl) | 2006-08-07 |
| CN1708297A (zh) | 2005-12-14 |
| AU2003283807B2 (en) | 2009-12-03 |
| TWI362260B (en) | 2012-04-21 |
| ATE526958T1 (de) | 2011-10-15 |
| KR20050075012A (ko) | 2005-07-19 |
| WO2004043454A1 (en) | 2004-05-27 |
| AU2009201384A1 (en) | 2009-05-07 |
| CA2505937A1 (en) | 2004-05-27 |
| MXPA05004752A (es) | 2005-08-02 |
| EP1562577A1 (en) | 2005-08-17 |
| CA2505937C (en) | 2011-07-26 |
| DK1562577T3 (da) | 2012-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1100589E (pt) | Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| KR950703951A (ko) | 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac) | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| ES2089027T3 (es) | Forma de dosificacion transmucosica. | |
| CY1112399T1 (el) | Ακετυλ-l-καρνιτινη για την προληψη και/ή τη θεραπεια περιφερικων νευροπαθειων που προκαλουνται απο θαλιδομιδη | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| ATE70439T1 (de) | Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien. | |
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| US2890984A (en) | Pharmaceutical composition containing 2-(1, 2, 3, 4-tetrahydro-1-naphthyl)imidazo-line | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| DE68911891D1 (de) | Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung. | |
| KR970025615A (ko) | 암 전이 억제제 | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
| CL2025001901A1 (es) | Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| CN105832724B (zh) | 吲哚醇在制备抗抑郁症药物中的用途 | |
| KR890014109A (ko) | 의약제 | |
| Carney et al. | Forty-two months experience of flupenthixol decanoate in the maintenance treatment of schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |